Aspirin or Rivaroxaban Thromboprophylaxis for Patients With Multiple Myeloma

Sponsor
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Study ID
NCT06580223
Phase
PHASE3
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 90 Years
Healthy Volunteers
Not accepted

Interventions

  • Aspirin 100mg — DRUG
    Aspirin, enteric coating of tablets, oral administration
  • Rivaroxaban 10mg — DRUG
    Rivaroxaban, tablets, oral administration.

Study Details

The aim of this study is to evaluate the efficacy and safety of aspirin and rivaroxaban in thromboprophylaxis in Chinese MM patients at high risk for MM-associated VTE.

Key Dates

First listed
Aug 30, 2024
Start date
Sep 1, 2025
Status verified
Jul 2025
Primary completion
Sep 1, 2027
Completion
Sep 1, 2027

Study Design

Enrollment
530 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION

Arms

  • Active Comparator: Aspirin
    Aspirin,100mg qd, for six months
  • Experimental: Rivaroxaban
    Rivaroxaban, 10mg qd, for six months

Primary Outcome Measure

Incidence of VTE within 6 months [ Time Frame: 6 months ]

Central Contacts

Find similar trials

Nationwide
Multiple myeloma trialsOncology trialsBlood cancer trials

Related Studies